GSK 📈 GlaxoSmithKline ADR - Overview
Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US37733W2044
GSK: Vaccines, Medicines, Influenza, Antibiotics, HIV, Oncology, Respiratory
GSK plc is a multinational healthcare company that engages in the research, development, and manufacture of a wide range of vaccines and medicines to prevent and treat various diseases. The company's product portfolio includes vaccines for shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic diseases, as well as medicines for HIV, oncology, respiratory/immunology, and other specialty areas. Additionally, GSK plc offers inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. Its operations are divided into two main segments: Commercial Operations and Total R&D, which enable the company to focus on both the development of new products and the commercialization of existing ones.
The company has established several strategic collaborations to advance its research and development efforts. For instance, it has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, which has the potential to provide more effective and longer-lasting protection against the flu. GSK plc also has partnerships with Wave Life Sciences and Elsie Biotechnologies, Inc to develop oligonucleotide platform technologies, which can be used to create new medicines for a range of diseases. Furthermore, the company has formed alliances with Relation to develop therapeutics for fibrotic diseases and osteoarthritis, and with Flagship Pioneering to discover novel medicines and vaccines. These collaborations demonstrate GSK plc's commitment to innovation and its willingness to work with other companies to advance the field of healthcare.
GSK plc has a long history, dating back to 1715, and is headquartered in Brentford, the United Kingdom. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. With a strong presence in the United Kingdom, the United States, and internationally, GSK plc is a major player in the pharmaceutical industry. Its common stock is listed on the New York Stock Exchange under the ticker symbol GSK, and the company's website can be found at https://www.gsk.com. The company's ISIN is US37733W2044, and it is classified under the GICS Sub Industry: Pharmaceuticals.
Additional Sources for GSK Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GSK Stock Overview
| Market Cap in USD | 68,759m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1986-07-09 |
GSK Stock Ratings
| Growth 5y | -6.87% |
| Fundamental | 36.2% |
| Dividend | 33.8% |
| Rel. Strength Industry | -994 |
| Analysts | 3.57/5 |
| Fair Price Momentum | 29.82 USD |
| Fair Price DCF | 43.62 USD |
GSK Dividends
| Dividend Yield 12m | 4.60% |
| Yield on Cost 5y | 4.12% |
| Annual Growth 5y | -5.43% |
| Payout Consistency | 91.4% |
GSK Growth Ratios
| Growth Correlation 3m | -84.2% |
| Growth Correlation 12m | -43.3% |
| Growth Correlation 5y | 34.4% |
| CAGR 5y | -2.19% |
| CAGR/Mean DD 5y | -0.15 |
| Sharpe Ratio 12m | -0.57 |
| Alpha | -25.84 |
| Beta | 0.53 |
| Volatility | 19.51% |
| Current Volume | 2413.8k |
| Average Volume 20d | 4090.7k |
As of January 02, 2025, the stock is trading at USD 33.82 with a total of 2,413,800 shares traded.
Over the past week, the price has changed by -0.88%, over one month by -1.43%, over three months by -15.12% and over the past year by -6.28%.
Partly, yes. Based on ValueRay Fundamental Analyses, GlaxoSmithKline ADR (NYSE:GSK) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 36.22 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GSK as of January 2025 is 29.82. This means that GSK is currently overvalued and has a potential downside of -11.83%.
GlaxoSmithKline ADR has received a consensus analysts rating of 3.57. Therefor, it is recommend to hold GSK.
- Strong Buy: 2
- Buy: 1
- Hold: 3
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, GSK GlaxoSmithKline ADR will be worth about 32.3 in January 2026. The stock is currently trading at 33.82. This means that the stock has a potential downside of -4.38%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 45.1 | 33.3% |
| Analysts Target Price | 39.6 | 17.2% |
| ValueRay Target Price | 32.3 | -4.4% |